Why GE HealthCare Just Paid $945 Million for a Fleet of Cyclotrons
GE HealthCare is dropping $945 million on a company most people have never heard of, and the reason comes down to a brutal physics problem: radioactive drugs start dying the moment they're made. Here's why the "final mile" is suddenly worth a billion-dollar bet.
The Radioactive FedEx Problem
Imagine ordering a pizza that loses half its toppings every two hours. That's essentially the challenge with PET radiopharmaceuticals: the radioactive tracers used in cancer imaging decay so fast that a missed delivery window doesn't just mean a late package. It means a useless one.
GE HealthCare just bet $945 million in cash that it can solve this problem. The company announced a deal to acquire SOFIE Biosciences, a Virginia-based radiopharmaceutical manufacturer with a nationwide network of production facilities and cyclotrons (the particle accelerators that produce medical isotopes). The deal is expected to close in the first half of 2027.
And the price tag tells you something important about where the radiopharmaceutical industry is headed.
What SOFIE Actually Does
SOFIE isn't a drug company in the traditional sense. Think of it more like a logistics and manufacturing backbone for the PET imaging world. The company operates 15 facilities with 21 cyclotrons spread across the U.S., from Albany, New York to Gilroy, California. Each site produces radioactive tracers, then ships them to hospitals and clinics before the doses decay into nothing.
The company also runs a theranostics-focused contract manufacturing site in Totowa, New Jersey, and recently opened a new PET manufacturing facility in Decatur, Illinois. SOFIE's plan has been to equip each site with dual cyclotrons and dual dispensing hot cells, building in redundancy so a single equipment failure doesn't leave patients without their scans.
GE HealthCare is buying SOFIE from private equity firm Trilantic North America. Notably, SOFIE will continue operating as an independent manufacturing partner for its existing customers, including other radiopharmaceutical companies. GE isn't pulling up the drawbridge; it's keeping the factory open for everyone.
The "Final Mile" Is the Whole Game
GE HealthCare described this acquisition as building a "final mile" footprint for PET radiopharmaceutical supply in the U.S. That phrase deserves unpacking, because it explains why this deal exists.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
In most industries, the last mile of delivery is annoying but manageable. Your Amazon package arrives a day late? Mildly frustrating. But in radiopharmaceuticals, the last mile is existential. PET tracers have half-lives measured in minutes to hours. Fluorine-18, the workhorse isotope in PET imaging, has a half-life of about 110 minutes. Every delay in packaging, transport, customs clearance, or hospital check-in directly reduces the dose's potency.
This creates a brutal constraint: you can't just build one giant factory and ship nationwide. You need regional production hubs close to the patients who need them. It's the opposite of how most pharmaceutical manufacturing works, where you centralize production for economies of scale. Radiopharmaceuticals force you to decentralize.
That's why SOFIE's scattered network of nearly two dozen cyclotrons is so valuable. It's not about any single facility; it's about geographic coverage.
GE's Bigger Chessboard
This deal doesn't exist in a vacuum. GE HealthCare has been methodically assembling a vertically integrated radiopharmaceutical platform over the past two years.
In late 2024, the company moved to acquire the remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, strengthening its PET and SPECT radiopharmaceutical footprint in Japan and Asia. It had already picked up MIM Software to add digital workflow and treatment-planning tools relevant to theranostics (the combination of diagnostic imaging and targeted therapy).
GE HealthCare also has an existing collaboration with Mayo Clinic focused on cancer theranostics, evaluating how to personalize radioligand therapy in advanced prostate cancer. The SOFIE acquisition gives GE something it didn't have before: control over U.S. manufacturing and distribution for the tracers its imaging machines detect.
The deal also brings GE the U.S. rights to FAPI-74, an experimental PET imaging agent in late-stage testing with potential applications in cancer detection. The two companies already had a 2023 licensing agreement covering FAP-targeting radiotracers, so this acquisition builds on an existing relationship.
Everyone Wants to Own the Supply Chain
GE isn't the only company racing to lock down radiopharmaceutical manufacturing. The competitive landscape has shifted dramatically in the past two years, and the pattern is clear: manufacturing control is becoming a competitive moat.
Siemens Healthineers already operates PETNET Solutions, a network of 47 PET radiopharmacies primarily in the U.S. It recently completed the acquisition of Novartis's Advanced Accelerator Applications Molecular Imaging business, adding 13 to 14 manufacturing sites across Europe. That gives Siemens arguably the broadest PET manufacturing footprint on the planet.
Lantheus, another major player, closed multiple strategic transactions and in-licensing deals in 2024, adding five new pipeline assets. The company also pursued a merger with Curium, signaling ambitions well beyond its diagnostic imaging roots.
Even Cardinal Health is making upstream moves, beginning weekly production of actinium-225 (a key isotope for therapeutic radiopharmaceuticals) at its Center for Theranostics Advancement in Indianapolis.
The throughline is unmistakable: companies are trying to secure isotope supply, cyclotron capacity, and distributed manufacturing networks all at once. Whoever controls the supply chain controls access to patients.
Was $945 Million the Right Price?
Earlier reports had pegged SOFIE's valuation at roughly $1 billion, so the final price came in slightly below expectations. Analyst reaction has been broadly positive on strategy, cautious on execution.
The bull case is straightforward. SOFIE gives GE recurring revenue from diagnostic agents that get used repeatedly, unlike scanners that are one-time capital purchases. It also creates customer stickiness: if a hospital relies on GE's tracers delivered through SOFIE's network to feed GE's PET/CT scanners, switching costs get very real.
The bear case focuses on integration complexity. Radiopharmaceutical manufacturing is operationally demanding, requiring scarce radiochemists, nuclear pharmacists, and trained logistics personnel. Scaling this kind of network is hard, and the specialized workforce needed to run it is in short supply across the industry.
There's also a broader question about whether demand growth will materialize fast enough to justify the price. The radioligand therapy market is surging, and PET imaging demand is climbing with it. But growth in this sector is constrained less by clinical interest than by the ability to manufacture, transport, and administer doses reliably on a just-in-time basis. GE is essentially betting that if it builds the infrastructure, the patients will come.
The Bottom Line
The SOFIE acquisition is GE HealthCare's clearest signal yet that it views radiopharmaceuticals as a core business, not a side project. By owning the manufacturing network alongside its imaging hardware, software tools, and proprietary tracers, GE is positioning itself as something rare in healthcare: a company that controls the entire diagnostic workflow from molecule to machine to patient.
Whether that vertically integrated bet pays off depends on execution. But in a market where radioactive doses literally lose value with every passing minute, owning the final mile might be the smartest mile to own.
Clinical & Regulatory
4 min read
The $4 Billion ADC Bet That Just Hit a Wall
Daiichi Sankyo and Merck pulled their FDA application for a lung cancer ADC just two weeks before the decision date. The reason signals a seismic shift in how the FDA evaluates accelerated approvals, and dozens of ADC programs should be worried.
